RECRUITING

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

Description

The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).

Conditions

Sarcoma
Talk to us

Related Conditions:

Sarcoma

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).

Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

Condition
Sarcoma
Intervention / Treatment

-

Contacts and Locations

Charlotte

Levine Cancer Institute, Charlotte, North Carolina, United States, 28204

Winston-Salem

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States, 27103

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.
  • 2. All ages allowed
  • 3. Suspected or confirmed disease (must meet one of the criteria below):
  • 1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)
  • 2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery
  • 3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below:
  • * Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy
  • * Metastatic or unresectable sarcoma, with planned or currently receiving therapy
  • * Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy
  • * none

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Johann Hsu, MD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

2030-01